What is the primary driver of McKesson's revenue and profit growth in this period?

The primary driver is the Pharmaceutical Solutions segment, which benefited from market growth rates, increased drug utilization, price adjustments, and the successful integration of the D&K Healthcare Resources, Inc. acquisition. This segment's improved operating profit reflects higher gross margins due to evolving manufacturer agreements and increased sales of higher-margin generic drugs.

What is the impact of the Securities Litigation on McKesson's financial position?

The Securities Litigation is a significant factor. McKesson recorded a substantial pre-tax charge of $1.2 billion in the third quarter of 2005, and has an accrual of $1,183 million as of September 30, 2005, which the company believes is adequate to cover remaining exposure. While the company has made progress with settlements, the ultimate outcome could still materially impact financial position, results of operations, and cash flows.

How has McKesson's cash position and liquidity evolved?

McKesson's liquidity has strengthened significantly. Cash and cash equivalents increased substantially to $3.0 billion from $1.8 billion, supported by strong operating cash flows. The company also has access to substantial credit facilities, and had no amounts outstanding under its revolving credit or accounts receivable sales facilities at the period end, indicating a healthy liquidity position.

What are the key recent acquisitions and their financial impact?

McKesson acquired D&K Healthcare Resources for $478 million in August 2005, integrating it into the Pharmaceutical Solutions segment. They also acquired Medcon, Ltd. for $82 million, contributing to the Provider Technologies segment. Both acquisitions added goodwill and intangible assets and have begun to contribute to revenue and operating results.

MCK 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

McKesson Corporation's Form 10-Q for the period ending September 30, 2005, reveals a strong financial performance with significant year-over-year growth in both revenue and net income. The company experienced an 8% increase in quarterly revenue, reaching $21.6 billion, and a substantial 94% surge in net income to $167 million. This growth was primarily driven by the Pharmaceutical Solutions segment, which benefited from increased drug utilization, price adjustments, and successful acquisitions, notably D&K Healthcare Resources. The report also highlights McKesson's proactive management of its balance sheet, including a notable increase in cash and cash equivalents and strategic share repurchases, underscoring a commitment to shareholder value. However, investors should note the ongoing and significant impact of the Securities Litigation, which resulted in a substantial charge and continues to be a key contingent liability requiring ongoing monitoring. The company demonstrated robust operational execution across its segments, with the Pharmaceutical Solutions segment showing particular strength due to improved supplier agreements and the positive contribution of recent acquisitions. While the company is managing its financial resources effectively, with healthy operating cash flow and a manageable debt-to-capital ratio, the substantial accrual for the Securities Litigation remains a critical factor influencing profitability and cash flow. McKesson's ability to navigate these legal challenges while continuing to drive growth in its core businesses will be crucial for future performance.

Key Highlights

1Revenue for the quarter increased by 8% to $21.6 billion, and for the six months, it rose by 9% to $42.7 billion, primarily driven by the Pharmaceutical Solutions segment.
2Net income saw a significant jump of 94% year-over-year for the quarter, reaching $167 million, with diluted EPS increasing to $0.53.
3The company successfully integrated the acquisition of D&K Healthcare Resources, Inc., contributing to the growth in the Pharmaceutical Solutions segment.
4Cash and cash equivalents significantly increased to $3.0 billion at the end of the period, up from $1.8 billion at the prior year-end, indicating strong cash generation.
5A significant pre-tax charge of $1.2 billion related to Securities Litigation was recorded in the third quarter of 2005, with an additional $52 million net pre-tax reserve increase noted in the first half of 2006.
6The company repurchased $4.8 million shares for $169.2 million during the quarter under its stock repurchase programs, demonstrating a commitment to returning capital to shareholders.
7Operating profit for the Pharmaceutical Solutions segment increased by 69% for the quarter and 26% for the six months, reflecting improved gross margins and contributions from acquisitions.

MCKESSON CORP Quarterly Report for Q2 Ended Sep 30, 2005

Summary

Key Highlights

Frequently Asked Questions